Astrana Health Inc. - Common Stock (ASTH)

Competitors to Astrana Health Inc. - Common Stock (ASTH)

Amgen Inc. 

Amgen Inc. is a leading biotechnology company that competes with Astrana Health in the field of therapeutic development and biotechnology innovations. Both companies focus on developing novel health solutions, but Amgen has greater financial resources and a wider portfolio of established products, giving it an edge in research, marketing, and distribution. While Astrana Health is emerging with innovative therapies, Amgen's extensive pipeline, partnerships, and market presence provide it with a competitive advantage.

Bristol-Myers Squibb Company 

Bristol-Myers Squibb is a diversified biopharmaceutical company that competes with Astrana Health by focusing on the discovery, development, and delivery of innovative medicines, particularly in oncology, immunology, and cardiovascular disease. The company's powerful R&D pipeline and proven track record of successful drug launches allow them to lead the market and set standards for treatment. In comparison, while Astrana Health aims to innovate within the healthcare space, it lacks the same level of market presence and pioneering capabilities as Bristol-Myers Squibb.

Gilead Sciences, Inc. 

Gilead Sciences, Inc. is another prominent player in the biotechnology sector, focusing on antiviral drugs and therapies for serious conditions. While both Gilead and Astrana Health strive to innovate in drug development, Gilead's established relationships with healthcare providers and research institutions and their extensive experience in large-scale product commercialization provide them with a substantial advantage in the market. Thus, Gilead's resources and established product lines position them as a leader compared to Astrana.

Novartis AG 

Novartis AG is a global healthcare company that competes with Astrana Health primarily through its diverse range of pharmaceuticals and cutting-edge research initiatives. Novartis has a well-established global presence along with significant financial backing to support extensive clinical trials and marketing efforts. Their knowledge and strength in the industry create a formidable barrier to entry for smaller companies like Astrana Health, rendering Novartis as the industry leader in many therapeutic areas.

Regeneron Pharmaceuticals, Inc. 

Regeneron Pharmaceuticals, Inc. operates in a similar realm to Astrana Health, focusing on developing drugs for serious medical conditions. They both invest heavily in research, but Regeneron has an established reputation and a robust product line, including monoclonal antibodies and rare disease treatments. The company also possesses advanced technological capabilities in genetic engineering, such as their VelociSuite technologies, which enhances their drug discovery process, placing them in a more favorable competitive position compared to Astrana Health.